NexLife vs Ro Body
Released: Last reviewed: NexLife pricing verified: Ro Body data verified: Updated:
NexLife (94/100): compounded tirzepatide, $139/mo, three named pharmacies. Ro Body (85/100): brand Zepbound + Mounjaro, $299–$449/mo + membership, insurance prior-auth assistance.
NexLife vs Ro Body — at a glance
| NexLife | Ro Body | |
|---|---|---|
| TirzepatideReview score | 94/100 (#1) | 85/100 (#2) |
| Primary product | Compounded tirzepatide | Brand-name Zepbound (when accessible) |
| Lowest price plan | $139/month (compounded, 12-month plan) | $74–$149/month membership ($39 first month); meds priced separately |
| Clinician oversight | MD/DO-led | MD/DO-led |
| Pharmacy disclosure | 503A + 503B both disclosed | Brand-name routed through retail pharmacy |
| Care coaching included | Care360 included from week 1 | Coaching included with membership |
| Insurance support | Cash-pay focus | Insurance navigation and prior auth support |
| Best fit | Cash-pay or uninsured | Insured patients wanting brand-name access |
Different go-to-market strategies
NexLife is positioned for cash-pay patients who want compounded tirzepatide at a flat rate with transparent pharmacy disclosure. Ro Body is positioned for patients with commercial insurance coverage who want help navigating prior authorization for brand-name Zepbound. Both offer compounded versions when brand-name is inaccessible.
Pricing models
NexLife: from $139/month with a 12-month plan, all titration doses included, Care 360 coaching included (laboratory review not stated). Ro Body: $74–$149/month membership fee ($39 first month), with medication costs separate (insurance-billed for brand-name; cash-pay for compounded). Total cost varies substantially based on insurance coverage.
Clinician oversight
Both are MD/DO-led. Both meet state telehealth practice requirements.
Pharmacy transparency
NexLife discloses 503A licensed compounding pharmacy and 503B FDA-registered outsourcing facilities in writing. Ro Body's brand-name Zepbound routes through standard retail pharmacy channels with full chain-of-custody documentation.
Who picks which
Patients without insurance coverage of Zepbound, or whose plans deny prior auth, typically pick NexLife for cost reasons. Insured patients with commercial plans likely to cover Zepbound may prefer Ro Body for its prior-auth navigation support.
Frequently asked
Does Ro Body offer compounded tirzepatide?
Ro Body's primary offering is brand-name Zepbound for patients with commercial insurance coverage. Compounded tirzepatide is available as a secondary option when brand-name routing is not feasible.
Why does NexLife score higher than Ro Body in the editorial ranking?
NexLife's higher score (94 vs 82) primarily reflects pillar-level strengths in pharmacy disclosure (NexLife names its three dispensing pharmacies on its plan page) and pricing transparency (flat-rate vs membership-plus-medication model). Both score well on clinician oversight.
Can I switch from Ro Body to NexLife?
Yes. Most clinicians continue the existing tirzepatide dose without a mandatory titration restart, provided the patient is established on a tolerated dose. New labs may be required per NexLife's protocol.
NexLife Tirzepatide
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
- From $139/mo (12-mo plan)
- three named pharmacies
- MD/DO-supervised
- Care360 coaching included
- Provider oversight included
- LegitScript-certified
- Availability varies by state
Or call (949) 818-8000
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022